We are live on ! Find out more
LP

LMR Partners Portfolio holdings

AUM $45.4B
1-Year Est. Return 60.68%
This Fund
S&P 500
This Quarter Est. Return
-14.47%
1 Year Est. Return
+60.68%
3 Year Est. Return
+183.94%
5 Year Est. Return
+215.13%
10 Year Est. Return
+663.15%
AUM
$5.96B
AUM Growth
-$2.66B
Cap. Flow
-$2.46B
Cap. Flow %
-41.33%
Top 10 Hldgs %
19.41%
Holding
1,586
New
385
Increased
156
Reduced
122
Closed
320

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$45.3M
2
DELL icon
Dell
DELL
+$42.5M
3
JD icon
JD.com
JD
+$38.9M
4
TSM icon
TSMC
TSM
+$32.4M
5
ACC
American Campus Communities, Inc.
ACC
+$31.6M

Sector Composition

Rank Sector Weight
1 Technology 20.75%
2 Financials 9.38%
3 Healthcare 5.16%
4 Consumer Discretionary 4.89%
5 Communication Services 4.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CTXR icon
1101
Citius Pharmaceuticals
CTXR
$14.2M
$54K ﹤0.01%
+2,357
New +$64.6K
YELL
1102
DELISTED
Yellow Corporation Common Stock
YELL
$53K ﹤0.01%
+17,959
New +$72.9K
DRRX
1103
DELISTED
DURECT Corp
DRRX
$51K ﹤0.01%
+10,759
New +$51.4K
ORIC icon
1104
Oric Pharmaceuticals
ORIC
$1.24B
$51K ﹤0.01%
+11,277
New +$45K
SCOR icon
1105
Comscore
SCOR
$107M
$51K ﹤0.01%
+1,249
New +$51.9K
WVE icon
1106
Wave Life Sciences
WVE
$1.14B
$51K ﹤0.01%
+15,789
New +$30.4K
AVDL
1107
DELISTED
Avadel Pharmaceuticals
AVDL
$50K ﹤0.01%
20,500
CGC
1108
Canopy Growth
CGC
$390M
$50K ﹤0.01%
+1,763
New +$91.7K
HBIO icon
1109
Harvard Bioscience
HBIO
$27M
$50K ﹤0.01%
+1,401
New +$63.2K
VIRX
1110
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$50K ﹤0.01%
+12,931
New +$36.8K
KG
1111
Kestrel Group
KG
$70.1M
$48K ﹤0.01%
+1,240
New +$55.5K
ABOS icon
1112
Acumen Pharmaceuticals
ABOS
$159M
$47K ﹤0.01%
+10,092
New +$37.9K
ZVRA icon
1113
Zevra Therapeutics
ZVRA
$574M
$47K ﹤0.01%
+10,572
New +$48.2K
GATO
1114
DELISTED
Gatos Silver, Inc.
GATO
$47K ﹤0.01%
+16,549
New +$58.1K
ASLN
1115
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$46K ﹤0.01%
2,304
ATOS icon
1116
Atossa Therapeutics
ATOS
$23.5M
$45K ﹤0.01%
+2,782
New +$43.8K
LAB icon
1117
Standard BioTools
LAB
$303M
$43K ﹤0.01%
+27,176
New +$67.2K
RNAC icon
1118
Cartesian Therapeutics
RNAC
$229M
$43K ﹤0.01%
+1,094
New +$32.4K
NEUE
1119
DELISTED
NeueHealth
NEUE
$43K ﹤0.01%
+292
New +$42.5K
ANNX icon
1120
Annexon
ANNX
$841M
$42K ﹤0.01%
+11,121
New +$34K
CTMX icon
1121
CytomX Therapeutics
CTMX
$708M
$42K ﹤0.01%
+23,134
New +$44.3K
GAN
1122
DELISTED
GAN Ltd
GAN
$42K ﹤0.01%
+14,310
New +$53K
CTOS.WS
1123
DELISTED
Custom Truck One Source, Inc. Warrants, exerciseable for Common Stock
CTOS.WS
$42K ﹤0.01%
74,300
SMSI icon
1124
Smith Micro Software
SMSI
$14.1M
$41K ﹤0.01%
+419
New +$48.7K
ALLK
1125
DELISTED
Allakos
ALLK
$40K ﹤0.01%
+12,654
New +$47.3K

Similar funds

LMR Partners's Q2 2022 Portfolio in Review

As of Q2 2022, LMR Partners held 1,586 positions worth $5.96B, down 31% from $8.61B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

LMR Partners withdrew a net $2.46B in Q2 2022, closing 320 positions and reducing 122 holdings. Its most notable exit was Invesco QQQ Trust, an estimated $117M position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.

Against the trend, LMR Partners opened a new position in Microsoft worth $42.8M.

  • LMR Partners's largest Q2 2022 buy was Microsoft: 166,753 shares worth $42.8M.
  • LMR Partners added most to TSMC in Q2 2022, an estimated $32.4M increase.
  • LMR Partners's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $553M.
  • LMR Partners fully exited Invesco QQQ Trust in Q2 2022, selling an estimated $117M.
  • LMR Partners's ten largest holdings make up 19% of its $5.96B portfolio in Q2 2022.
  • LMR Partners opened 385 new positions and closed 320 in Q2 2022.
  • LMR Partners's portfolio value fell 31% quarter-over-quarter to $5.96B.

Based on LMR Partners's 13F filing for Q2 2022, filed 15 Aug 2022.